INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients

 

 Buy Article Permissions and Reprints

Abstract

Objective Our objective was to determine if treatment with pravastatin prevents preeclampsia in pregnant patients at risk of preeclampsia.

Material and Methods The study was performed in four major tertiary hospitals in Surabaya, Bandung, and Makassar between 2017 and 2021. Pregnant women at high risk of developing preeclampsia were recruited and randomized into an intervention group and control group. The control group received low-dose aspirin (80 mg) and calcium (1 g) daily, while the intervention group received additional pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery. The pregnancy was followed until delivery, and the clinical data were collected. The primary outcome was the occurrence of preeclampsia.

Result A total of 173 people participated in this study, including 86 in the control group and 87 in the pravastatin group. The pravastatin group had a significantly lower rate of preterm preeclampsia (13.8 vs. 26.7%; p = 0.034; odds ratio [OR] = 0.034, 95% confidence interval [CI] = 0.202–0.905) and preterm birth (16.1 vs. 36%; p = 0.003; OR = 0.340, 95% CI = 0.165–0.7), mostly indicated preterm birth. Preeclampsia occurred later in the pravastatin group than in the control group (36.39 + 2.32 vs. 34.89 + 3.38 weeks, p = 0.048). Overall, the pravastatin group showed better perinatal outcomes. Neonates with low Apgar scores (<7) at 1 minute (5.7 vs. 25.6%, p = 0.000) and 5 minutes (2.3 vs. 25.6%, p = 0.028) were significantly less common in the pravastatin group. Additionally, the rate of low birthweight babies (<2,500 g) was lower in the pravastatin group (27.6 vs. 40.7%; p = 0.069).

Conclusion Pravastatin (20 mg bid) significantly reduces the risk of preterm preeclampsia and preterm birth in women at a high risk of developing preeclampsia.

Key Points

• This is an open-label multicenter RCT to evaluate pravastatin effect to prevent preeclampsia.

• Pravastatin significantly reduces the risk of preterm preeclampsia (PE) and preterm birth in high risk PE women.

• Pravastatin had a beneficial effect on perinatal outcomes, including Apgar scores and birth weight.

Publication History

Received: 23 February 2022

Accepted: 11 March 2022

Accepted Manuscript online:
15 March 2022

Article published online:
06 June 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Poon LC, Shennan A, Hyett JA. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 (Suppl. 01) 1-33
  CrossrefPubMedGoogle Scholar
• 2 ACOG. Gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (76) 168-186
  PubMedGoogle Scholar
• 3 Brown MA, Magee LA, Kenny LC. et al; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018; 72 (01) 24-43
  CrossrefPubMedGoogle Scholar
• 4 Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol 2022; 226 (2S): S1171-S1181
  CrossrefPubMedGoogle Scholar
• 5 Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol 2016; 11 (06) 1102-1113
  CrossrefPubMedGoogle Scholar
• 6 Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ 2019; 366: l2381
  CrossrefPubMedGoogle Scholar
• 7 Sibai B, Dekker G, Kupferminc M, Way AS. Pre-eclampsia. Lancet 2005; 365 (9461): 785-799
  CrossrefPubMedGoogle Scholar
• 8 Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124 (07) 1094-1112
  CrossrefPubMedGoogle Scholar
• 9 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365 (9461): 785-799
  CrossrefPubMedGoogle Scholar
• 10 Levine RJ, Maynard SE, Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (07) 672-683
  CrossrefPubMedGoogle Scholar
• 11 Redman CWG, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30 (Suppl A): S38-S42
  CrossrefPubMedGoogle Scholar
• 12 Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia. Am J Obstet Gynecol 2022; 226 (2S): S867-S875
  CrossrefPubMedGoogle Scholar
• 13 Ahmed A, Ramma W. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?. Br J Pharmacol 2015; 172 (06) 1574-1586
  CrossrefPubMedGoogle Scholar
• 14 Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 2015; 213 (4, Suppl): 9.e1, S9–S11
  PubMedGoogle Scholar
• 15 Kim S-Y, Ryu H-M, Yang J-H. et al. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 2007; 22 (05) 873-877
  CrossrefPubMedGoogle Scholar
• 16 Reddy A, Suri S, Sargent IL, Redman CWG, Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One 2009; 4 (02) e4453
  CrossrefPubMedGoogle Scholar
• 17 Ramma W, Ahmed A. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 2014; 101-102 (01) 153-160
  CrossrefPubMedGoogle Scholar
• 18 Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?. Biochem Soc Trans 2009; 37 (Pt 6): 1237-1242
  CrossrefPubMedGoogle Scholar
• 19 Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010; 74 (05) 818-826
  CrossrefPubMedGoogle Scholar
• 20 Vahedian-Azimi A, Karimi L, Reiner Ž, Makvandi S, Sahebkar A. Effects of statins on preeclampsia: a systematic review. Pregnancy Hypertens 2021; 23: 123-130
  CrossrefPubMedGoogle Scholar
• 21 Katsi V, Georgountzos G, Kallistratos MS. et al. The role of statins in prevention of preeclampsia: a promise for the future?. Front Pharmacol 2017; 8 (May): 247
  CrossrefPubMedGoogle Scholar
• 22 Putra RA, Effendi JS, Permadi W, Bandiara R, Fauziah PN. Role of statin as inducer of Hmox-1 system in treatment of preeclampsia. Cell Mol Biol 2018; 64 (10) 1-4
  CrossrefPubMedGoogle Scholar
• 23 Brownfoot FC, Tong S, Hannan NJ. et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 2015; 66 (03) 687-697 , discussion 445
  CrossrefPubMedGoogle Scholar
• 24 Akbar MIA, Yosediputra A, Pratama RE. et al. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study. J Matern Fetal Neonatal Med 2021; 31: 1-8
  CrossrefPubMedGoogle Scholar
• 25 Akbar MIA, Yosediputra A, Pratama RE. et al. INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia and Its Effects on sFlt1/PlGF Levels [published online ahead of print, 2021 Oct 19].. Am J Perinatol 2021; DOI: 10.1055/a-1673-5603.
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Akbar MIA, Yosediputra A, Pratama RE. et al. INOVASIA study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1/PlGF levels. Am J Perinatol 2021; (e-pub ahead of print) DOI: 10.1055/a-1673-5603.
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. 2014; 36 (06) 506-509
  PubMedGoogle Scholar
• 28 Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007; 29 (11) 906-908
  PubMedGoogle Scholar
• 29 Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs 2012; 72 (06) 773-788
  CrossrefPubMedGoogle Scholar
• 30 Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64 (04) 496-509
  CrossrefPubMedGoogle Scholar
• 31 Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007; 29 (11) 906-908
  CrossrefPubMedGoogle Scholar
• 32 Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. Elsevier; 2016. Accessed April 4, 2019 at: https://www.sciencedirect.com/science/article/pii/S1933287416302343
  Google Scholar
• 33 FDA. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins _ FDA. FDA Drug Safety Podcast. Published January 14, 2022. Accessed March 1, 2022 at: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy
  PubMedGoogle Scholar
• 34 Costantine MM, Cleary K, Hebert MF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 2016; 214 (06) 720.e1-720.e17
  CrossrefPubMedGoogle Scholar
• 35 Ahmed A, Williams DJ, Cheed V. et al; StAmP trial Collaborative Group. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG 2020; 127 (04) 478-488
  CrossrefPubMedGoogle Scholar
• 36 Winterfeld U, Allignol A, Panchaud A. et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 2013; 120 (04) 463-471
  CrossrefPubMedGoogle Scholar
• 37 Costantine MM, Cleary K. Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric–Fetal Pharmacology Research Units Network*. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121 (2 Pt 1): 349-353
  CrossrefPubMedGoogle Scholar
• 38 Costantine MM, West H, Wisner KL. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers (OPRC) Network, Bethesda, MD. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol 2021; 225 (06) 666.e1-666.e15
  CrossrefPubMedGoogle Scholar
• 39 Itoh H. Obesity and risk of preeclampsia. Med J Obstet Gynecol 2014; 2 (02) 1024
  PubMedGoogle Scholar
• 40 Rocha RS, Alves JAG, Maia E Holanda Moura SB. et al. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy. J Perinat Med 2017; 45 (07) 843-849
  CrossrefPubMedGoogle Scholar
• 41 Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32 (02) 138-146
  CrossrefPubMedGoogle Scholar
• 42 Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn 2014; 34 (07) 618-627
  CrossrefPubMedGoogle Scholar
• 43 Lovgren TR, Dugoff L, Galan HL. Uterine artery Doppler and prediction of preeclampsia. Clin Obstet Gynecol 2010; 53 (04) 888-898
  CrossrefPubMedGoogle Scholar
• 44 Antsaklis A, Daskalakis G. Uterine artery Doppler in the prediction of preeclampsia and adverse pregnancy outcome. Donald Sch J Ultrasound in Obs Gynecol 2010; 4 (June): 117-122
  CrossrefPubMedGoogle Scholar
• 45 Pedroso MA, Palmer KR, Hodges RJ, Costa FDS, Rolnik DL. Uterine artery doppler in screening for preeclampsia and fetal growth restriction. Rev Bras Ginecol Obstet 2018; 40 (05) 287-293
  Article in Thieme ConnectPubMedGoogle Scholar
• 46 ACOG Committee on Practice Bulletins–Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99 (01) 159-167
  PubMedGoogle Scholar
• 47 de Onis M, Habicht JP. Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. Am J Clin Nutr 1996; 64 (04) 650-658
  CrossrefPubMedGoogle Scholar
• 48 Kupferminc MJ, Kliger C, Rimon E. et al. Pravastatin is useful for prevention of recurrent severe placenta-mediated complications—a pilot study. J Matern Fetal Neonatal Med 2021; 1-7
  CrossrefPubMedGoogle Scholar
• 49 Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97 (12) 1129-1135
  CrossrefPubMedGoogle Scholar
• 50 Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J. et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101 (12) 2711-2719
  CrossrefPubMedGoogle Scholar
• 51 Kumasawa K, Ikawa M, Kidoya H. et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108 (04) 1451-1455
  CrossrefPubMedGoogle Scholar
• 52 Antonopoulos AS, Margaritis M, Shirodaria C, Antoniades C. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012; 108 (05) 840-848
  Article in Thieme ConnectPubMedGoogle Scholar
• 53 de Alwis N, Beard S, Mangwiro YT. et al. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. Pregnancy Hypertens 2020; 20: 83-91
  CrossrefPubMedGoogle Scholar
• 54 Mendoza M, Ferrer-Oliveras R, Bonacina E. et al. Evaluating the effect of pravastatin in early-onset fetal growth restriction: a nonrandomized and historically controlled pilot study. Am J Perinatol 2021; 38 (14) 1472-1479
  Article in Thieme ConnectPubMedGoogle Scholar
• 55 Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18 (11) 1519-1530
  CrossrefPubMedGoogle Scholar
• 56 Girardi G. Can statins prevent pregnancy complications?. J Reprod Immunol 2014; 101-102 (01) 161-167
  CrossrefPubMedGoogle Scholar
• 57 Akbar MIA, Yosediputra A, Pratama RE. et al. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study[published online ahead of print, 2021 Jan 31]. J Matern Fetal Neonatal Med 2021; 1-8 DOI: 10.1080/14767058.2021.1879785.
  CrossrefPubMedGoogle Scholar
• 58 Bateman BT, Hernandez-Diaz S, Fischer MA. et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035
  CrossrefPubMedGoogle Scholar
• 59 Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. National Birth Defects Prevention Study. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A 2008; 146A (20) 2701-2705
  CrossrefPubMedGoogle Scholar
• 60 Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39 (06) 397-412
  CrossrefPubMedGoogle Scholar
• 61 Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet Gynecol Surv 2018; 73 (01) 40-55 DOI: 10.1097/OGX.0000000000000522.
  CrossrefPubMedGoogle Scholar